These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 11348951)

  • 1. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia.
    Dresser LD; Niederman MS; Paladino JA
    Chest; 2001 May; 119(5):1439-48. PubMed ID: 11348951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization.
    Corrêa JC; Badaró R; Bumroongkit C; Mera JR; Dolmann AL; Juárez Martínez LG; Mayrinck LR; Tamez R; Yang JY
    Clin Ther; 2003 May; 25(5):1453-68. PubMed ID: 12867221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gatifloxacin in the treatment of community-acquired pneumonias: a comparative trial of ceftriaxone, with or without macrolides, in hospitalized adult patients with mild to moderately severe pneumonia.
    Mendonça JS; Yamaguti A; Corrêa JC; Badaró R
    Braz J Infect Dis; 2004 Feb; 8(1):90-100. PubMed ID: 15286880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia.
    Bhavnani SM; Ambrose PG
    Diagn Microbiol Infect Dis; 2008 Jan; 60(1):59-64. PubMed ID: 17889491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database.
    Brown RB; Iannini P; Gross P; Kunkel M
    Chest; 2003 May; 123(5):1503-11. PubMed ID: 12740267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study.
    Tamm M; Todisco T; Feldman C; Garbino J; Blasi F; Hogan P; de Caprariis PJ; Hoepelman IM
    Clin Microbiol Infect; 2007 Feb; 13(2):162-171. PubMed ID: 17328728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial.
    Lloyd A; Holman A; Evers T
    Curr Med Res Opin; 2008 May; 24(5):1279-84. PubMed ID: 18358083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability.
    Lode H; File TM; Mandell L; Ball P; Pypstra R; Thomas M;
    Clin Ther; 2002 Nov; 24(11):1915-36. PubMed ID: 12501883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cost-effectiveness analysis of ceftriaxone and cefotaxime in the treatment of community-acquired pneumonia].
    García-Contreras F; Del-Angel-García G; Ramírez Cuenca A; Malváez-Valdes M; Vega Yáñez A; Amato D
    Rev Invest Clin; 2000; 52(4):418-26. PubMed ID: 11061104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing gatifloxacin and clarithromycin in pneumonia symptom resolution and process of care.
    Dean NC; Sperry P; Wikler M; Suchyta MS; Hadlock C
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1164-9. PubMed ID: 16569825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.
    File TM; Eckburg PB; Talbot GH; Llorens L; Friedland HD
    Int J Antimicrob Agents; 2017 Aug; 50(2):247-251. PubMed ID: 28599867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia.
    Friedman H; Song X; Crespi S; Navaratnam P
    Value Health; 2009; 12(8):1135-43. PubMed ID: 19695010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An economic evaluation of sequential i.v./po moxifloxacin therapy compared to i.v./po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia.
    Drummond MF; Becker DL; Hux M; Chancellor JV; Duprat-Lomon I; Kubin R; Sagnier PP
    Chest; 2003 Aug; 124(2):526-35. PubMed ID: 12907538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study.
    Llop CJ; Tuttle E; Tillotson GS; LaPlante K; File TM
    Hosp Pract (1995); 2017 Feb; 45(1):1-8. PubMed ID: 28064542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: results from the CAP-IN trial.
    Samsa GP; Matchar DB; Harnett J; Wilson J
    Chest; 2005 Nov; 128(5):3246-54. PubMed ID: 16304269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective, randomized, multicenter comparative study of clinafloxacin versus a ceftriaxone-based regimen in the treatment of hospitalized patients with community-acquired pneumonia.
    Petermann W; Alegre-Martin J; Odenholt I; Phillips MJ; Willcox PA; Tack K; Trostmann U; Welling L
    Scand J Infect Dis; 2001; 33(11):832-7. PubMed ID: 11760164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of ceftriaxone in the treatment of community-acquired pneumonia in adult hospital patients. A pharmaco-economic study based on a meta-analysis.
    Wessels F; Anderson AN; Ebrahim O
    S Afr Med J; 1998 Mar; 88(3):251-5. PubMed ID: 9608289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
    File TM; Segreti J; Dunbar L; Player R; Kohler R; Williams RR; Kojak C; Rubin A
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1965-72. PubMed ID: 9303395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of antibiotic treatment strategies for community-acquired pneumonia: results from a cluster randomized cross-over trial.
    van Werkhoven CH; Postma DF; Mangen MJ; Oosterheert JJ; Bonten MJ;
    BMC Infect Dis; 2017 Jan; 17(1):52. PubMed ID: 28068956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.